Amylyx Pharmaceuticals, Inc. announced today that the first participants have been dosed in the PHOENIX global trial evaluating the safety and efficacy of AMX0035 (sodium phenylbutyrate and taurursodiol) in people with amyotrophic lateral sclerosis (ALS). PHOENIX, a follow-up to the CENTAUR trial, will take place at approximately 65 sites in Europe and the US, and represents a major step forward in collaboration between the American Northeast ALS Consortium (NEALS) and the European group Treatment Research Initiative to Cure ALS (TRICALS).

Read their announcement

“I’m enthusiastic about the opportunity to conduct a trial of this size and scope within the NEALS network of trial-ready research centers primarily based in North America, in partnership with TRICALS in Europe, as we continue to evaluate AMX0035 as a potential new therapeutic,” said Co-Chair of the PHOENIX Steering Committee Sabrina Paganoni, MD, PhD, who is an investigator at the Sean M. Healey & AMG Center for ALS at Mass General and member of the Executive Committee of NEALS and Co-Chair .